361 related articles for article (PubMed ID: 17150303)
1. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
Burstein HJ; Prestrud AA; Seidenfeld J; Anderson H; Buchholz TA; Davidson NE; Gelmon KE; Giordano SH; Hudis CA; Malin J; Mamounas EP; Rowden D; Solky AJ; Sowers MR; Stearns V; Winer EP; Somerfield MR; Griggs JJ;
J Clin Oncol; 2010 Aug; 28(23):3784-96. PubMed ID: 20625130
[TBL] [Abstract][Full Text] [Related]
2. Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
van Hellemond IEG; Geurts SME; Tjan-Heijnen VCG
Curr Treat Options Oncol; 2018 Apr; 19(5):26. PubMed ID: 29704066
[TBL] [Abstract][Full Text] [Related]
3. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
Farias AJ; Du XL
Med Oncol; 2016 Feb; 33(2):19. PubMed ID: 26786154
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant treatment in hormone receptor-positive early breast cancer: New approaches of endocrine therapy.
Nardin S; Ruelle T; Giannubilo I; Del Mastro L
Tumori; 2024 Jun; 110(3):162-167. PubMed ID: 38112006
[TBL] [Abstract][Full Text] [Related]
5. Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer.
Nabholtz JM; Mouret-Reynier MA; Durando X; Van Praag I; Nayl B; Ferriere JP; Chollet P
Indian J Surg Oncol; 2010 Jan; 1(1):19-26. PubMed ID: 22930614
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer.
Mundhenke C; Schem C; Jonat W
Breast Care (Basel); 2008; 3(5):317-324. PubMed ID: 20824026
[TBL] [Abstract][Full Text] [Related]
7. A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy.
Pieters HC; Green E; Khakshooy S; Sleven M; Stanton AL
PLoS One; 2019; 14(1):e0210972. PubMed ID: 30703119
[TBL] [Abstract][Full Text] [Related]
8. 5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast cancer: A population-based database study (2006-2016).
van den Biggelaar YJPG; Kuiper JG; van der Sangen MJC; Luiten EJT; Siesling S; van Herk-Sukel M; Voogd AC; Mesters I
Breast Dis; 2023; 42(1):331-339. PubMed ID: 37927248
[TBL] [Abstract][Full Text] [Related]
9. Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: a systematic review and meta-analysis.
Wu P; Lv W
Front Endocrinol (Lausanne); 2024; 15():1254213. PubMed ID: 38481446
[TBL] [Abstract][Full Text] [Related]
10. Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.
Symonds LK; Davidson NE
J Natl Cancer Inst; 2023 Nov; 115(11):1240-1242. PubMed ID: 37480258
[No Abstract] [Full Text] [Related]
11. Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research.
Conforti F; Pala L; De Pas T; Zattarin E; Catania C; Cocorocchio E; Rossi G; Laszlo D; Colleoni M; Zambelli A; Hortobagyi GN; Cortes J; Piccart MJ; Dowsett M; Gelber RD; Viale G
Clin Cancer Res; 2024 Mar; 30(6):1093-1103. PubMed ID: 37906083
[TBL] [Abstract][Full Text] [Related]
12. Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
Sehdev S; Martin G; Sideris L; Lam W; Brisson S
Curr Oncol; 2009 Jul; 16 Suppl 2(Suppl 2):S14-23. PubMed ID: 19672417
[TBL] [Abstract][Full Text] [Related]
13. Understanding the impact of breast cancer adjuvant endocrine therapy on cognitive function: a work in progress.
Ganz PA
Br J Cancer; 2016 Apr; 114(9):953-5. PubMed ID: 27115566
[No Abstract] [Full Text] [Related]
14. PRRX1 drives tamoxifen therapy resistance through induction of epithelial-mesenchymal transition in MCF-7 breast cancer cells.
Dong J; Lv Z; Chen Q; Wang X; Li F
Int J Clin Exp Pathol; 2018; 11(5):2629-2635. PubMed ID: 31938377
[TBL] [Abstract][Full Text] [Related]
15. A joint model for multistate disease processes and random informative observation times, with applications to electronic medical records data.
Lange JM; Hubbard RA; Inoue LYT; Minin VN
Biometrics; 2015 Mar; 71(1):90-101. PubMed ID: 25319319
[TBL] [Abstract][Full Text] [Related]
16. Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer.
Bender CM; Gentry AL; Brufsky AM; Casillo FE; Cohen SM; Dailey MM; Donovan HS; Dunbar-Jacob J; Jankowitz RC; Rosenzweig MQ; Sherwood PR; Sereika SM
Oncol Nurs Forum; 2014 May; 41(3):274-85. PubMed ID: 24769592
[TBL] [Abstract][Full Text] [Related]
17. Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada.
Verma S; Sehdev S; Joy AA
Curr Oncol; 2007 Dec; 14 Suppl 1(Suppl 1):S3-10. PubMed ID: 18087606
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant endocrine therapy for early breast cancer.
Andreetta C; Smith I
Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
[TBL] [Abstract][Full Text] [Related]
19. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
